Effect of Evolocumab on Coronary Plaque Characteristics

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.

Also called NCT04710368

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 137 participants (enrolled count) (from the registry)
Sponsor
Annapoorna Kini (from the registry)
Registry
  • NCT NCT04710368
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04710368. Allocation not applicable; no masking; primary purpose basic science. Start 2021-05-04 (actual); primary completion 2022-10-28 (actual). Results posted on 2023-05-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Evolocumab on Coronary Plaque Characteristics
Acronym
YELLOW III
Intervention (Drug)
Evolocumab Injections
Lead sponsor
Annapoorna Kini (class: other)

Record details

Record id
cardio:ct-nct04710368
Content hash
179c70ee9065b9fe56d821ed9ca304f8a41dd5483781a15f4b0bd1835832d5a2